Durata Therapeutics, Inc. to Host Conference Call and Webcast on December 11, 2012 at 9:00AM ET to Present Preliminary Top-Line Results From Its DISCOVER 1 Study
Published: Dec 11, 2012
CHICAGO--(BUSINESS WIRE)--Durata Therapeutics, Inc. (NASDAQ: DRTX) today announced that it will host a conference call and webcast at 9:00am Eastern Time on Tuesday, December 11, 2012 to present preliminary top-line results from its DISCOVER 1 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”) Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria. To access the call, please dial 866-632-4021 for participants in the U.S. or Canada and 404-991-3968 for international callers, reference passcode: 79502265. A replay of the call may be accessed through December 25, 2012 by dialing 800-585-8367 for callers in the U.S. and Canada and (404) 537-3406 for international callers, reference passcode: 79502265. The conference call will also be webcast live on Durata’s website, www.duratatherapeutics.com.